UPDATE: RBC Capital Starts Editas Medicine (EDIT) at Sector Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Editas Medicine (EDIT) Misses Q1 EPS by 13c, Revenues Beat
May 5, 2021 7:24 AM EDTEditas Medicine (NASDAQ: EDIT) reported Q1 EPS of ($0.86), $0.13 worse than the analyst estimate of ($0.73). Revenue for the quarter came in at $6.5 million versus the consensus estimate of $5.77 million.
Our team is making tremendous progress towards discovering, developing, and manufacturing novel genome editing medicines, including excellent forward momentum this quarter for our two clinical-stage... More
